BioCentury | Mar 21, 2016
Clinical News

QPI-1002: Phase III started

...Switzerland) an option to license exclusive, worldwide rights to QPI-1002 (see BioCentury, Aug. 23, 2010). SBI Biotech Co. Ltd....
BioCentury | Mar 21, 2016
Clinical News

QPI-1002: Phase II started

...Switzerland) an option to license exclusive, worldwide rights to QPI-1002 (see BioCentury, Aug. 23, 2010). SBI Biotech Co. Ltd....
BioCentury | Nov 9, 2015
Clinical News

QPI-1007: Phase II/III started

...Biocon Ltd. (NSE:BIOCON; BSE:BIOCON), Bangalore, India Kunshan RiboQuark Pharmaceutical Technology Co. Ltd. , Kunshan, China SBI Biotech Co. Ltd....
BioCentury | Oct 15, 2015
Distillery Therapeutics

Therapeutics: p53

...Next steps include testing whether p53 knockdown prevents radiation-induced development of other cancers in mice. SBI Biotech Co. Ltd....
BioCentury | Apr 9, 2015
Strategy

De Novo in Tokyo

...Medical Science at the University of Tokyo , and Ken-Ichi Arai, director and chairman of SBI Biotech Co. Ltd....
...Japan Johnson & Johnson (NYSE:JNJ), New Brunswick, N.J. Novo Nordisk A/S (CSE:NVO; NYSE:NVO), Bagsvaerd, Denmark SBI Biotech Co. Ltd....
BioCentury | Aug 4, 2014
Clinical News

QPI-1002: Phase II data

...Orphan Drug designation in the U.S. and Europe to prevent DGF in kidney transplant patients. SBI Biotech Co. Ltd....
BioCentury | Jul 29, 2014
Clinical News

QPI-1002 misses in graft function Phase II

...The Quark Pharmaceuticals Inc. subsidiary of SBI Biotech Co. Ltd. (Tokyo, Japan) said a single IV dose of QPI-1002...
BioCentury | Jul 24, 2014
Cover Story

It is an RNA world

...I Topical on skin or eye drops SBI Biotech Co. Ltd....
...CK6A) gene Phase I Transplantation Renal transplant SBI Biotech Co. Ltd....
...Pharmaceuticals Inc., a wholly owned subsidiary of SBI Biotech Co. Ltd....
BioCentury | Jul 21, 2014
Clinical News

QPI-1007: Phase IIa started

...India BioSpring GmbH , Frankfurt, Germany Kunshan RiboQuark Pharmaceutical Technology Co. Ltd. , Kunshan, China SBI Biotech Co. Ltd....
BioCentury | Jan 13, 2014
Financial News

RiboQuark completes venture financing

...Life Sciences Co. Ltd. (Kunshan, China) and Quark Pharmaceuticals Inc. Quark is a subsidiary of SBI Biotech Co. Ltd....
Items per page:
1 - 10 of 16
BioCentury | Mar 21, 2016
Clinical News

QPI-1002: Phase III started

...Switzerland) an option to license exclusive, worldwide rights to QPI-1002 (see BioCentury, Aug. 23, 2010). SBI Biotech Co. Ltd....
BioCentury | Mar 21, 2016
Clinical News

QPI-1002: Phase II started

...Switzerland) an option to license exclusive, worldwide rights to QPI-1002 (see BioCentury, Aug. 23, 2010). SBI Biotech Co. Ltd....
BioCentury | Nov 9, 2015
Clinical News

QPI-1007: Phase II/III started

...Biocon Ltd. (NSE:BIOCON; BSE:BIOCON), Bangalore, India Kunshan RiboQuark Pharmaceutical Technology Co. Ltd. , Kunshan, China SBI Biotech Co. Ltd....
BioCentury | Oct 15, 2015
Distillery Therapeutics

Therapeutics: p53

...Next steps include testing whether p53 knockdown prevents radiation-induced development of other cancers in mice. SBI Biotech Co. Ltd....
BioCentury | Apr 9, 2015
Strategy

De Novo in Tokyo

...Medical Science at the University of Tokyo , and Ken-Ichi Arai, director and chairman of SBI Biotech Co. Ltd....
...Japan Johnson & Johnson (NYSE:JNJ), New Brunswick, N.J. Novo Nordisk A/S (CSE:NVO; NYSE:NVO), Bagsvaerd, Denmark SBI Biotech Co. Ltd....
BioCentury | Aug 4, 2014
Clinical News

QPI-1002: Phase II data

...Orphan Drug designation in the U.S. and Europe to prevent DGF in kidney transplant patients. SBI Biotech Co. Ltd....
BioCentury | Jul 29, 2014
Clinical News

QPI-1002 misses in graft function Phase II

...The Quark Pharmaceuticals Inc. subsidiary of SBI Biotech Co. Ltd. (Tokyo, Japan) said a single IV dose of QPI-1002...
BioCentury | Jul 24, 2014
Cover Story

It is an RNA world

...I Topical on skin or eye drops SBI Biotech Co. Ltd....
...CK6A) gene Phase I Transplantation Renal transplant SBI Biotech Co. Ltd....
...Pharmaceuticals Inc., a wholly owned subsidiary of SBI Biotech Co. Ltd....
BioCentury | Jul 21, 2014
Clinical News

QPI-1007: Phase IIa started

...India BioSpring GmbH , Frankfurt, Germany Kunshan RiboQuark Pharmaceutical Technology Co. Ltd. , Kunshan, China SBI Biotech Co. Ltd....
BioCentury | Jan 13, 2014
Financial News

RiboQuark completes venture financing

...Life Sciences Co. Ltd. (Kunshan, China) and Quark Pharmaceuticals Inc. Quark is a subsidiary of SBI Biotech Co. Ltd....
Items per page:
1 - 10 of 16